Zhejiang Starry Pharmaceutical Co.,Ltd.

SHSE:603520 Stock Report

Market Cap: CN¥4.3b

Zhejiang Starry PharmaceuticalLtd Future Growth

Future criteria checks 5/6

Zhejiang Starry PharmaceuticalLtd is forecast to grow earnings and revenue by 61.7% and 20.7% per annum respectively. EPS is expected to grow by 61.6% per annum. Return on equity is forecast to be 15.7% in 3 years.

Key information

61.7%

Earnings growth rate

61.6%

EPS growth rate

Pharmaceuticals earnings growth19.0%
Revenue growth rate20.7%
Future return on equity15.7%
Analyst coverage

Low

Last updated30 Apr 2024

Recent future growth updates

Recent updates

Market Might Still Lack Some Conviction On Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE:603520) Even After 31% Share Price Boost

Mar 12
Market Might Still Lack Some Conviction On Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE:603520) Even After 31% Share Price Boost

Is Zhejiang Starry PharmaceuticalLtd (SHSE:603520) Using Too Much Debt?

Feb 28
Is Zhejiang Starry PharmaceuticalLtd (SHSE:603520) Using Too Much Debt?

Earnings and Revenue Growth Forecasts

SHSE:603520 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20264,128602N/A7872
12/31/20253,341382N/A5085
12/31/20242,774229N/A4902
3/31/20242,27247-104179N/A
12/31/20232,19644-22245N/A
9/30/20232,385-56-167113N/A
3/31/20232,180-147-444-27N/A
12/31/20222,131-76-551-78N/A
9/30/20222,066124-427143N/A
6/30/20222,087232-334176N/A
3/31/20222,15333933427N/A
12/31/20212,000324205509N/A
9/30/20211,631260149303N/A
6/30/20211,50025565233N/A
3/31/20211,440258-8152N/A
12/31/20201,36723921174N/A
9/30/20201,37023131190N/A
6/30/20201,39521795262N/A
3/31/20201,30617584242N/A
12/31/20191,309170113247N/A
9/30/20191,24214672208N/A
6/30/20191,09812224138N/A
3/31/201998811266209N/A
12/31/20188909429192N/A
9/30/201879498-5134N/A
6/30/20187429435170N/A
3/31/201871277-1769N/A
12/31/201771183N/A32N/A
9/30/201771284N/A35N/A
6/30/201771284N/A-22N/A
3/31/201769879N/A-4N/A
12/31/201667376N/A8N/A
9/30/201671681N/A34N/A
6/30/201669174N/A76N/A
3/31/201666160N/A37N/A
12/31/201569669N/A95N/A
12/31/201465868N/A144N/A
12/31/201368664N/A75N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 603520's forecast earnings growth (61.7% per year) is above the savings rate (2.9%).

Earnings vs Market: 603520's earnings (61.7% per year) are forecast to grow faster than the CN market (24.2% per year).

High Growth Earnings: 603520's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 603520's revenue (20.7% per year) is forecast to grow faster than the CN market (14.7% per year).

High Growth Revenue: 603520's revenue (20.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 603520's Return on Equity is forecast to be low in 3 years time (15.7%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.